Commercial strategies in cardiovascular and metabolic diseases-successful market positioning at company and brand level becomes paramount

Datamonitor expects commercial strategies in the cardiovascular and metabolic markets to become increasingly important as the markets mature. The report details strategies used by pharmaceutical companies to capture market share, to differentiate brands from the competition, for revenue maximization and for the defense of brand revenues from generic competition.

Prasugrel: a flawed approval?

On July 10, 2009, the FDA approved Effient (prasugrel) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. However, the approval has surprised many physicians as prasugrel has had a tortuous clinical development program, with important questions raised over its clinical benefits and the trial design.

Technology Transfer Strategies: Maximizing the returns from new technologies

Technology transfer is a long-established part of early-stage research within the pharmaceutical and biotechnology industries. Although technology transfer offices have traditionally been associated with inefficiency and a lack of commercial judgment, recent trends have shown improvements in staffing, expertise and service levels.

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors

‘Evolving Trends in Biopharmaceutical Licensing' is a report published by Business Insights that provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies.

The Autoimmune Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Autoimmune disorders have been one of the most prominent growth segments in the pharma industry over the last decade. A growing patient population and high levels of unmet need are the main drivers of market growth, and novel biologics are increasingly helping to fulfill patient need, with their high cost helping to drive market sales.

The Top 10 Contract Research Organizations:Positioning, performance and SWOT analyses

Cost containment and regulatory pressures within the pharma industry are driving R&D outsourcing across the globe. Clinical obstacles to approval have become more significant due to the growing availability of existing generic treatments, and the trend to adopt Health Economics Outcomes Research (HEOR) assessments is increasing the complexity of clinical research.

Market developments, outsourcing hotspots and growth strategies

This report aims to identify the hotspots and profile the leading players in the global pharmaceutical contract manufacturing market.

How pharmaceutical and biotech industry could  survive and thrive in a world where new media technology creates our lives and our future?

Social networks may shape the future of pharmaceutical and biotechnology industry

We live in a time of mass media. The internet and computers of all shapes and sizes could soon replace the written word, television and radio. We pay our bills through internet-banking. We read newspapers on their internet sites. We make new acquaintances through virtual networks.

New technologies, growth opportunities, and the future market outlook

‘Innovations in In-Vitro Diagnostics' provides an in-depth analysis of emerging opportunities and potential clinical advances across the diagnostics markets of coronary heart disease, heart failure, bacterial infections and viral infections.

Accelerating Lead Generation: Emerging technologies and strategies

This report provides an in-depth examination of state-of-the-art technologies for lead generation.

The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016.

Managing cost containment and safeguarding productivity

For several years, drug developers have been under intense pressure to introduce new products in an environment of escalating R&D costs, blockbuster patent expiration and resulting generic competition, increasingly complex science, heightened regulatory scrutiny, and other pressures. Now, however, the global economic meltdown has added new imperatives for drug makers to cut costs.

Maximizing opportunities towards achieving clinical success

For the last few years the biggest pharma companies have started to bring new technologies for drug safety prediction into the discovery phases of research. This report will describe these technologies, their place in the drug discovery and development paradigm and their value for improving drug safety.

Forecast Analysis

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success

Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist physicians, differentiating by indications is the key to success. Datamonitor has surveyed gastroenterologists, rheumatologists and dermatologists on attribute and brand perceptions

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.

Drug repositioning strategies: a different approach to innovation

With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.

Forecast Analysis

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.